Should I buy Integra Lifesciences Holdings (IART) stock or is it too late?
⭐ The most reliable of them, either direction: UBS — 59% of its targets hit on this sector (76 calls tested). It aims for $19 (+37 %), call made on July 29, 2026, maturing on July 29, 2027 (77 d ago).
Firm-by-firm track record on Integra Lifesciences Holdings
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Morgan Stanley | 80 % | +38.3 % | 5 | $27 +95% |
| Citigroup | 100 % | +31.9 % | 7 | $15 +8% |
| B of A Securities | 67 % | +15.8 % | 6 | $18 +30% |
| JP Morgan | 60 % | +10.8 % | 5 | $13 -6% |
| JMP Securities | 36 % | -18.8 % | 14 | $25 +81% |
| Credit Suisse | 75 % | +17.2 % | 8 | — |
| Jefferies | 67 % | +1.9 % | 6 | — |
✅ Reasons to believe
- Median price target $18, i.e. +30% from the current price ($14).
- The most reliable firm on IART, Citigroup (100% hit rate, 7 scored calls), targets $15 (call made on October 5, 2026, maturing on October 5, 2027) (+8%) in its most recent call, and $11 (call made on October 31, 2025, maturing on October 31, 2026) (-21%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 5 ratings, 5 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on IART
Median target $18 (+30%) · 5 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Integra Lifesciences Holdings now?
We won't decide for you. The facts: 0% of analysts rate it a buy, median target $18 (+30%), and Citigroup (most reliable on IART, 100%) targets $15. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Integra Lifesciences Holdings?
Not according to analysts: the median target ($18) is still +30% above the current price ($14) (most reliable on IART: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Integra Lifesciences Holdings still worth investing in?
It depends on the gap between the price ($14) and its estimated value: analysts target $18 on median (+30%), with 0% buys (most reliable on IART: Citigroup, 100%). Cross-check with their real reliability on IART and the cautions above. Information, not advice.
What's the main risk in buying IART?
The consensus is not unanimous: of 5 ratings, 5 are neutral.
→ Go deeper: the full Integra Lifesciences Holdings profile (consensus, analyst reliability, price target, performance).